We are comparing Harpoon Therapeutics Inc. (NASDAQ:HARP) and ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) on their profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation. They both are Biotechnology companies, competing one another.

Earnings & Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harpoon Therapeutics Inc.	4.75M	58.88	27.37M	-0.94	0.00
ACADIA Pharmaceuticals Inc.	223.81M	18.08	245.19M	-1.44	0.00

Table 1 shows gross revenue, earnings per share (EPS) and valuation of the two companies.

Profitability

Table 2 provides us Harpoon Therapeutics Inc. and ACADIA Pharmaceuticals Inc.’s net margins, return on assets and return on equity.

	Net Margins	Return on Equity	Return on Assets
Harpoon Therapeutics Inc.	-576.21%	0%	0%
ACADIA Pharmaceuticals Inc.	-109.55%	-77.1%	-66.6%

Liquidity

Harpoon Therapeutics Inc.’s Current Ratio and Quick Ratio are 3.8 and 3.8 respectively. The Current Ratio and Quick Ratio of its competitor ACADIA Pharmaceuticals Inc. are 8.8 and 8.8 respectively. ACADIA Pharmaceuticals Inc. therefore has a better chance of paying off short and long-term obligations compared to Harpoon Therapeutics Inc.

Analyst Ratings

Harpoon Therapeutics Inc. and ACADIA Pharmaceuticals Inc. Ratings and Recommendations are available on the next table.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Harpoon Therapeutics Inc.	0	0	2	3.00
ACADIA Pharmaceuticals Inc.	0	3	5	2.63

The average price target of Harpoon Therapeutics Inc. is $23.5, with potential upside of 104.53%. ACADIA Pharmaceuticals Inc. on the other hand boasts of a $35 average price target and a 24.47% potential upside. The data provided earlier shows that Harpoon Therapeutics Inc. appears more favorable than ACADIA Pharmaceuticals Inc., based on analyst belief.

Institutional and Insider Ownership

Harpoon Therapeutics Inc. and ACADIA Pharmaceuticals Inc. has shares held by institutional investors as follows: 35.2% and 98.64%. Harpoon Therapeutics Inc.’s share held by insiders are 0.5%. Insiders Comparatively, held 0.1% of ACADIA Pharmaceuticals Inc. shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Harpoon Therapeutics Inc.	18.45%	0%	0%	0%	0%	26%
ACADIA Pharmaceuticals Inc.	13.05%	17.87%	30.78%	86.2%	16.84%	66.05%

For the past year Harpoon Therapeutics Inc.’s stock price has smaller growth than ACADIA Pharmaceuticals Inc.

Summary

Harpoon Therapeutics Inc. beats ACADIA Pharmaceuticals Inc. on 7 of the 12 factors.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia that are in phase III clinical trials; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.